Utility of limited sampling strategies for anticancer agents in the clinical arena: A systematic review

Current Cancer Therapy Reviews

Volumn 5, Issue 1, 2009, Pages 45-66

  Pattar, Rumi ^a,b   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Anticancer agents; Antineoplastic agents; Chemotherapy; Limited sampling; Optimal sampling; Sparse sampling

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; INTERFERON; IRINOTECAN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ALBERS SCHOENBERG DISEASE; AREA UNDER THE CURVE; BRAIN TUMOR; BREAST CANCER; BURKITT LYMPHOMA; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONTINUOUS INFUSION; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; DRUG RESEARCH; EMBASE; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; EWING SARCOMA; GALLBLADDER CANCER; GYNECOLOGIC CANCER; HODGKIN DISEASE; HUMAN; HURLER SYNDROME; LARGE CELL LYMPHOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT HISTIOCYTOSIS; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TERATOMA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; METACHROMATIC LEUKODYSTROPHY; METASTASIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAMPLING; SARCOMA; SINGLE DRUG DOSE; SOFT TISSUE CANCER; SOLID TUMOR; STATISTICAL ANALYSIS; STOMACH CANCER; SYSTEMATIC REVIEW; THALASSEMIA; VALIDATION PROCESS; VISCERAL METASTASIS;

EID: 65649133091     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339409787314081     Document Type: Review

References (77)

1. Panetta JC, Iacono LC, Adamson PC, et al. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res 2003; 9: 5068-77.
2. Suarez-Kurtz G, Estrela RE, and Salvadori MC. Prednisolone. Limited sampling strategies for estimating pharmacokinetic parameters. Ther Drag Monit 2004; 26: 16-22.
3. Panetta JC, Wilkinson M, Pui CH, et al. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn 2002; 29: 171-88.
4. Loh GW, Ting LS, Ensom MHH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet 2007; 46: 471-94.
5. Ting LS, Villeneuve E, and Ensom MHH. Beyond cyclosporine: A systematic review of limited sampling strategies for other immuno-suppressants. Ther Drag Monit 2006; 28: 419-30.
6. Ting LSL, Partovi N, Ensom M, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharamcotherapy 2006; 26(9): 1232-40.
7. van Warmerdam LJC, ten Bokkel Huinink WW, Maes RA, et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 1994; 120: 427-33.
8. Williams PJ, Ette EI. In: Kimko HC, Duffull SB Ed, Simulation for designing clinical trials: A pharmacokinetic-pharmacodynamic modeling perspective. New York, NY, Marcel Dekker 2003; 73-103.
9. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-34.
10. Kirstein MN, Panetta JC, Gajjar A, et al. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemother Pharmacol 2005; 55: 433-38.
11. US Preventive Services Task Force (ed). Guide to preventive services: Report of the US Preventive Services Task Force (ed 2). Baltimore, MD, Williams & Wilkins 1996.
12. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-9.
13. Schuler U, Schroer S, Kühnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: Is drag monitoring warranted? Bone Marrow Transplant 1994; 14: 759-65.
14. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843-50.
15. Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20: 347-54.
16. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386-89.
17. Bullock JM, Smith PF, Booker BM, et al. Development of a pharmacokinetic and bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drag Monit 2006; 28: 62-6.
18. Nguyen L, Leger F, Lennon S, et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006; 57: 191-8.
19. Dupuis LL, Sibbald C, Schechter T, et al. IV bulsufan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Morrow Transplant 2008; 14: 576-82.
20. Liliemark J, Albertioni F, Juliusson G, et al. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Cancer Chemother Pharmacol 1996; 38: 536-40.
21. Egorin MJ, Forrest A, Belani CP, et al. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 1989; 49: 3129-33.
22. Bailie P, Bruno R, Schellens JHM, et al. Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 1997; 3: 1535-8.
23. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96.
24. Ratain MJ, Robert J, and van der Vijgh WJ. Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991; 9: 871-6.
25. Eksborg S. Limited sampling model for plasma level monitoring with special reference to epirubicin (Famorubicin). Acta Oncol 1990; 29: 339-42.
26. Jakobsen P, Steiness E, Bastholt L, et al. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1991; 28: 63-8.
27. Ralph LD, Thomson AH, Dobbs NA, et al. Maximum a posteriori bayesian estimation of epirubicin clearance by limited sampling. Br J Clin Pharmacol 2004; 57: 764-72.
28. Gentili D, Zucchetti M, Torri V, et al. A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother Pharmacol 1993; 32: 482-6.
29. Strömgren AS, Sørensen BT, Jakobsen P, et al. A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 1993; 32: 226-30.
30. Millward MJ, Newell DR, Yuen KM, et al. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother Pharmacol 1995; 37: 161-7.
31. Minami H, Ando Y, Sakai S, et al. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 1995; 13: 191-9.
32. Holz JB, Köppler H, Schmidt L, et al. Limited sampling models for reliable estimation of etoposide area under the curve. Eur J Cancer 1995; 31A: 1794-8.
33. Perdaems N, Bachaud JM, Rouzaud P, et al. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Eur J Clin Pharmacol 1998; 54: 677-83.
34. Tranchand B, Amsellem C, Chatelut E, et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999; 43: 316-22.
35. Port RE, Edler L, Herrmann R, et al. Pharmacokinetics of 5-fluorouracil after short systemic infusion: Plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve. Ther Drug Monit 1991; 13: 96-102.
36. Moore MJ, Bunting P, Yuan S, et al. Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit 1993; 15: 394-9.
37. Di Paolo A, Danesi R, Vannozzi F, et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627-37.
38. Gusella M, Ferrazzi E, Ferrari M, et al. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. Ther Drug Monit 2002; 24: 425-31.
39. Sasaki Y, Mizuno S, Fujii H, et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995; 86: 117-23.
40. Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 1995; 36: 463-72.
41. Mick R, Gupta E, Vokes EE, et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012-19.
42. Yamamoto N, Tamura T, Nishiwaki Y, et al. Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. Clin Cancer Res 1997; 3: 1087-92.
43. Sloan JA, Atherton P, Reid J, et al. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide. Cancer Chemother Pharmacol 2001; 48: 241-9.
44. Poujol S, Pinguet F, Ychou M, et al. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. Oncol Rep 2007; 18: 1613-21.
45. Nath CE, Shaw PJ, Montgomery K, et al. Population pharmacokinetics of melphalan in pediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2007; 64: 151-64.
46. Odoul F, Le Guellec C, Lamagnere JP, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol 1999; 13: 595-604.
47. Faltaos DW, Hulot JS, Urien S, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 2006; 58: 626-33.
48. Piard C, Bressolle F, Fakhoury M, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2007; 60: 609-20.
49. Dupuis C, Mercier C, Yang C, et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anti-Cancer Drugs 2008; 19: 267-73.
50. Ackland SP, Choi KE, Ratain MJ, et al. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol 1988; 6: 1192-6.
51. van Warmerdam LJC, Verweij J, Rosing H, et al. Limited sampling models for topotecan pharmacokinetics. Ann Oncol 1994; 5: 259-64.
52. Minami H, Beijnen JH, Verweij J, et al. Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res 1996; 2: 43-6.
53. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamic (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 1996; 18: 352-61.
54. Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: Intraindividual variability in total drug. Cancer Chemother Pharmacol 2000; 46: 375-81.
55. Léger F, Loos WJ, Fourcade J, et al. Factors affecting pharmacokinetic variability of oral topotecan: A population analysis. Br J Cancer 2004; 90: 343-7.
56. Turner PK, Iacono LC, Panetta JC, et al. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemother Pharmacol 2006; 57: 475-82.
57. Ratain MJ, and Vogelzang NJ. Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep 1987; 71: 935-39.
58. Sabot C, Marquet P, Debord J, et al. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Clin Pharmacol 1998; 54: 171-5.
59. Nguyen L, Tranchand B, Puozzo C, et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002; 53: 459-68.
60. Gauvin A, Pinguet F, Culine S, et al. A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. Anticancer Drugs 2002; 13: 473-80.
61. Joel SP, Dolega-Ossowski E, Jones K, et al. The bioavailability of oral etoposide, during prolonged administration and development of a limited sampling strategy for estimation of AUC after an oral dose. Proc Am Assoc Cancer Res. 1991; 32:178.
62. Joel SP, Heap L, Clarke PI, et al. A limited sampling strategy for the calculation of etoposide pharmacokinetics. Proc Am Soc Clin Oncol 1990; 9: 290.
63. Lum BL, Lane KJ, Synold TW, et al. Validation of a limited sampling model to determine etoposide area under the curve. Pharmacotherapy 1997; 17:887-90.
64. Davidson A, Gowing R, Lowis S, et al. Phase II study of 21 day schedule oral etoposide in children. Eur J Cancer 1997; 33: 1816-22.
65. Eksborg S, Palm C, and Björk O. A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anticancer Drugs 2000; 11: 129-36.
66. van Warmerdam LJC, Creemers GJ, Rodenhuis S, et al. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol 1996; 38: 254-60.
67. Balasubramanian P, Chandy M, Krishnamoorthy R, et al. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 821-5.
68. Ando Y, Minami H, Saka H, et al. Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. Jpn J Cancer Res 1996; 87: 856-61.
69. Zucchetti M, Pagani O, Torri V, et al. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. Clin Cancer Res 1995; 1: 1517-24.
70. Kerbusch T, de Kraker J, Mathôt RAA, et al. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin Pharmacokinet 2001; 40: 615-25.
71. Vaughan WP, Carey D, Perry S, et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619-24.
72. Du Bois D and Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Internal Med 1916; 17: 863-71.
73. Kaestner SA, and Sewell GJ. Chemotherapy dosing part I: Scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol) 2007; 19: 23-37.
74. Felici A, Verweij J, and Sparreboom A. Dosing strategies for anticancer drugs: The good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677-84.
75. van den Bongard HJ, Mathôt RA, Beijnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345-67.
76. Garattini S. Pharmacokinetics in cancer chemotherapy. Eur J Cancer 2007; 43: 271-82.
77. Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: Does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265-79.